
\begin{tabular}[t]{llll}
\toprule
Â  & ET & Palbociclib & Ribociclib\\
\midrule
 & (N=44) & (N=246) & (N=106)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age at treatment start}}\\
\hspace{1em}Mean (SD) & 59.7 (12.7) & 59.2 (11.7) & 58.2 (10.7)\\
\hspace{1em}Median [Min, Max] & 61.5 [34.0, 85.0] & 60.0 [28.0, 84.0] & 58.0 [32.0, 79.0]\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Menopausal status}}\\
\hspace{1em}Post-menopause & 36 (82 \%) & 201 (82 \%) & 83 (78 \%)\\
\hspace{1em}Pre-menopause & 8 (18 \%) & 41 (17 \%) & 21 (20 \%)\\
\hspace{1em}Peri-menopause & NA & 1 (0 \%) & NA\\
\hspace{1em}Missing & 0 (0\%) & 3 (1.2\%) & 2 (1.9\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Bone Only metastases}}\\
\hspace{1em}No & NA & 161 (65 \%) & 74 (70 \%)\\
\hspace{1em}Yes & NA & 85 (35 \%) & 32 (30 \%)\\
\hspace{1em}Missing & 44 (100\%) & 0 (0\%) & 0 \vphantom{1} (0\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Visceral metastasis}}\\
\hspace{1em}No & NA & 121 (49 \%) & 49 (46 \%)\\
\hspace{1em}Yes & NA & 125 (51 \%) & 57 (54 \%)\\
\hspace{1em}Missing & 44 (100\%) & 0 (0\%) & 0 (0\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Stage}}\\
\hspace{1em}I & 3 (7 \%) & 22 (9 \%) & 7 (7 \%)\\
\hspace{1em}II & 21 (48 \%) & 75 (30 \%) & 22 (21 \%)\\
\hspace{1em}III & 11 (25 \%) & 74 (30 \%) & 18 (17 \%)\\
\hspace{1em}IV & 2 (5 \%) & 65 (26 \%) & 46 (43 \%)\\
\hspace{1em}Missing & 7 (15.9\%) & 10 (4.1\%) & 13 (12.3\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Drug/Combination}}\\
\hspace{1em}Anastrozol & 3 (7 \%) & NA & NA\\
\hspace{1em}Exemestane & 4 (9 \%) & NA & NA\\
\hspace{1em}Fulvestrant & 5 (11 \%) & 180 (73 \%) & 10 (9 \%)\\
\hspace{1em}Letrozol & 32 (73 \%) & 66 (27 \%) & 96 (91 \%)\\
\bottomrule
\end{tabular}
